GHRP-6 triggered a GH pulse in men, women and children after one dose

How does GHRP-6 work?

GHRP-6 works by activating GHS-R1a, the same receptor that the gut hormone ghrelin activates. GHRP-6 was the original synthetic growth hormone secretagogue. A 1984 study first characterized it as a hexapeptide that dose-dependently released GH in rats, monkeys, calves and lambs through direct action on the pituitary ^[1].

Ghrelin's job in the body is broader than GH release. Ghrelin is the primary orexigenic, appetite-driving signal from the stomach to the hypothalamus, and it also has roles in gastric motility and metabolic signaling.

GHRP-6 does not selectively trigger only the GH-release arm of that pathway. GHRP-6 triggers the receptor, and the receptor does what it evolved to do. The same receptor action produces both the reliable GH pulse and the appetite effect that forums treat as a bonus.

Is GHRP-6 cytoprotective in humans?

GHRP-6's cytoprotective effects come from cell and animal studies, and no human randomized controlled trial has tested them for any clinical endpoint ^[5].

Preclinical work has characterized a second receptor target, CD36, through which GHRP-6 activates PI-3K/AKT1 prosurvival signaling, producing anti-inflammatory and cardioprotective effects in animal models ^[5]. That work is the basis for the "cytoprotective peptide" framing that circulates online. The biology is real in cell and animal systems. The CD36 pathway also features in the hexarelin evidence review.

Does GHRP-6 raise growth hormone in humans?

Yes. A single dose of GHRP-6 produces a measurable GH pulse in adult men, adult women and children ^[2]⁠^[3]. The human data fall into two categories, pharmacology and diagnostics.

The pharmacology case is strong. In the 37-person trial, a 1 mcg/kg IV dose produced a robust GH-stimulatory response in adult men, in adult women across all menstrual-cycle stages, and in prepubertal children, with the response size independent of sex and age ^[2]. Alpha-1 adrenergic blockade with prazosin amplified the release, while beta-blockade and clonidine did nothing to it ^[2]. The GH response runs through a specific, reproducible neuroendocrine pathway, not a vague or inconsistent one.

The largest GHRP-6 study in the literature used GHRP-6 combined with GHRH as a clinical test to distinguish GH-deficient adults from healthy controls ^[3]. The 125 patients with organic pituitary disease averaged a GH peak of 4.1 mcg/L, versus 59.2 mcg/L in 125 matched healthy adults, with no adverse effects reported and better discrimination than the older insulin tolerance test ^[3]. The dataset is large and well controlled, but its purpose was diagnostic classification, not measuring what happens to someone using GHRP-6 repeatedly to change body composition.

What is GHRP-6's half-life?

GHRP-6 has a fast distribution half-life of 7.6 minutes and an elimination half-life of 2.5 hours after a single IV bolus, in a Phase I study of nine healthy men ^[4]. The study tested 100, 200 and 400 mcg/kg doses and found dose-proportional exposure and no safety signals ^[4].

The Phase I study gives the clearest GHRP-6 dosing data available. It is a real, if small, human safety readout, and the closest thing to an answer on how GHRP-6 behaves in the body.

Does chronic GHRP-6 use improve body composition?

No randomized trial has tested weeks or months of GHRP-6 against a body-composition or recovery endpoint, so the chronic effect is unknown. Every human study cited below measured a single acute pulse, not a durable outcome.

None of the three human studies covers repeated dosing, subcutaneous administration, IGF-1 trajectories over time, body composition measurement, or any population resembling a healthy adult self-dosing for recovery or physique goals.

GHRP-6's evidence grade of C, moderate, reflects that split. The acute mechanism and pharmacokinetics are proven. The chronic, self-directed use that drives demand for GHRP-6 has no trial evidence behind it at all. The GHRP-2 evidence review covers that compound's own record.

Does GHRP-6 spare cortisol and prolactin?

The claim that GHRP-6 releases little cortisol or prolactin is only partially proven, and only acutely. The founding 1984 study found no concomitant prolactin, LH, FSH or TSH release, in animals ^[1].

None of the human studies cited below tracked cortisol or prolactin across repeated subcutaneous dosing, which is how people use GHRP-6.

Can GHRP-6's appetite effect be separated from its GH effect?

No. GHRP-6's hunger and its GH pulse are outputs of the identical receptor activation at GHS-R1a, so the two cannot be cleanly separated.

Forum framing treats the hunger as a selling point for bulking phases and a nuisance to manage during cutting phases, as if appetite were an optional dial. The receptor biology argues against that framing. Because GHRP-6 mimics ghrelin at GHS-R1a, appetite stimulation is not a downstream side effect that happens to co-occur with GH release. It is the same signaling event.

Anyone using GHRP-6 while trying to avoid appetite stimulation, or dosing around meals to dodge it, is fighting the mechanism GHRP-6 is built on, not a side effect adjacent to it. The same pattern runs through the human trials of ghrelin agonists and appetite.

What side effects do GHRP-6 users report?

GHRP-6 users report water retention, transient flushing after injection, numbness or lethargy, and shifts in insulin sensitivity with sustained GH elevation. These reports come from users, not controlled chronic trials, so they count as anecdotal signal rather than established fact.

The reported effects are mechanistically coherent with a ghrelin-receptor agonist that also drives sustained GH output. None of the three human studies cited below addresses any of them.

How do GHRP-6 trial doses compare with forum doses?

GHRP-6 trials dosed per kilogram by IV injection, and those doses do not resemble the flat 100 to 300 mcg subcutaneous doses circulating on forums. Peñalva et al. used 1 mcg/kg IV ^[2]. Cabrales et al. tested 100, 200 and 400 mcg/kg IV, an order of magnitude different dosing logic, calculated per kilogram rather than as a flat dose ^[4].

Both trials were intravenous, single-dose, and conducted in supervised clinical settings. None of the studies cited below used subcutaneous administration, repeated dosing, or the multi-week protocols that self-dosing forums describe. Anyone extrapolating a chronic subcutaneous regimen from these trials is extrapolating past what the data cover, not following them.

What is still unknown about GHRP-6?

Everything downstream of GHRP-6's acute GH pulse remains unanswered by controlled human trials:

• IGF-1. Whether chronic GHRP-6 use raises IGF-1 in a sustained, meaningful way.
• Body composition. Whether any acute GH pulse translates into measurable body composition change.
• Cortisol and prolactin. What happens to both over weeks of repeated dosing, as opposed to a single IV bolus.
• Ghrelin-mediated effects. What chronic exposure does to gut motility, gastric acid and insulin sensitivity in a healthy, non-clinical population.
• Cytoprotection. Whether the anti-inflammatory signaling seen in animal and cell models has any human correlate at all ^[5].

Until a controlled trial answers these questions, GHRP-6's acute GH-releasing effect is real and well characterized, and everything downstream of that pulse remains a mechanistically plausible extrapolation rather than a demonstrated outcome.